An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia - Full Text View

Sponsored by:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00111891

Purpose

This is a 3-week trial in normal healthy or lipid clinic patients studying a novel approach to treating dyslipidemia.

Condition	Intervention	Phase
Dyslipidemia	Drug: niacin (+) laropiprant Drug: Comparator: placebo (unspecified)	Phase II

Drug Information available for: Laropiprant Niacin Niacin hydrochloride Lipids

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	A Dose Ranging Study to Evaluate the Tolerability of MK0524 (Niacin (+) Laropiprant) and Its Effects on Niacin-Induced Acute Flushing in Lipid Clinic Patients and/or Normal Healthy Subjects

Further study details as provided by Merck:

Primary Outcome Measures:

Acute cutaneous symptoms induced by niacin for 7 days. [ Time Frame: 7 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Detailed Description:

The duration of treatment is 7 days.

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

A condition which, in the opinion of the investigator, might pose a risk to the patient or interfere with participating in the study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00111891

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

Responsible Party:	Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences )
Study ID Numbers:	2005_032, MK0524A-032
Study First Received:	May 26, 2005
Last Updated:	July 30, 2008
ClinicalTrials.gov Identifier:	NCT00111891
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Nicotinic Acids
Metabolic Diseases
Flushing
Healthy

Metabolic disorder
Niacin
Dyslipidemias
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on January 16, 2009